211 related articles for article (PubMed ID: 25907661)
21. A molecular basis for neurofibroma-associated skeletal manifestations in NF1.
Ma Y; Gross AM; Dombi E; Pemov A; Choi K; Chaney K; Rhodes SD; Angus SP; Sciaky N; Clapp DW; Ratner N; Widemann BC; Rios JJ; Elefteriou F
Genet Med; 2020 Nov; 22(11):1786-1793. PubMed ID: 32601387
[TBL] [Abstract][Full Text] [Related]
22. Modulation of spine fusion with BMP-2, MEK inhibitor (PD0325901), and zoledronic acid in a murine model of NF1 double inactivation.
Bobyn JD; Deo N; Little DG; Schindeler A
J Orthop Sci; 2021 Jul; 26(4):684-689. PubMed ID: 32713795
[TBL] [Abstract][Full Text] [Related]
23. Shedding New Light: Novel Therapies for Common Disorders in Children with Neurofibromatosis Type I.
Pillay-Smiley N; Fletcher JS; de Blank P; Ratner N
Pediatr Clin North Am; 2023 Oct; 70(5):937-950. PubMed ID: 37704352
[TBL] [Abstract][Full Text] [Related]
24. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells.
Mashour GA; Ratner N; Khan GA; Wang HL; Martuza RL; Kurtz A
Oncogene; 2001 Jan; 20(1):97-105. PubMed ID: 11244508
[TBL] [Abstract][Full Text] [Related]
25. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
Beert E; Brems H; Daniëls B; De Wever I; Van Calenbergh F; Schoenaers J; Debiec-Rychter M; Gevaert O; De Raedt T; Van Den Bruel A; de Ravel T; Cichowski K; Kluwe L; Mautner V; Sciot R; Legius E
Genes Chromosomes Cancer; 2011 Dec; 50(12):1021-32. PubMed ID: 21987445
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration.
Brown AP; Carlson TC; Loi CM; Graziano MJ
Cancer Chemother Pharmacol; 2007 Apr; 59(5):671-9. PubMed ID: 16944149
[TBL] [Abstract][Full Text] [Related]
27. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
28. Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1.
Osum SH; Watson AL; Largaespada DA
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669386
[TBL] [Abstract][Full Text] [Related]
29. The role of nerve microenvironment for neurofibroma development.
Liao CP; Pradhan S; Chen Z; Patel AJ; Booker RC; Le LQ
Oncotarget; 2016 Sep; 7(38):61500-61508. PubMed ID: 27517146
[TBL] [Abstract][Full Text] [Related]
30. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
Simmons BH; Lee JH; Lalwani K; Giddabasappa A; Snider BA; Wong A; Lappin PB; Eswaraka J; Kan JL; Christensen JG; Shojaei F
Cancer Chemother Pharmacol; 2012 Aug; 70(2):213-20. PubMed ID: 22684718
[TBL] [Abstract][Full Text] [Related]
31. Hyperactive RAS/PI3-K/MAPK Signaling Cascade in Migration and Adhesion of Nf1 Haploinsufficient Mesenchymal Stem/Progenitor Cells.
Zhou Y; He Y; Sharma R; Xing W; Estwick SA; Wu X; Rhodes SD; Xu M; Yang FC
Int J Mol Sci; 2015 Jun; 16(6):12345-59. PubMed ID: 26039236
[TBL] [Abstract][Full Text] [Related]
32. Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1.
Monroe CL; Dahiya S; Gutmann DH
Annu Rev Pathol; 2017 Jan; 12():53-74. PubMed ID: 28135565
[TBL] [Abstract][Full Text] [Related]
33. Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice.
Coulpier F; Pulh P; Oubrou L; Naudet J; Fertitta L; Gregoire JM; Bocquet A; Schmitt AM; Wolkenstein P; Radomska KJ; Topilko P
Transl Res; 2023 Nov; 261():16-27. PubMed ID: 37331503
[TBL] [Abstract][Full Text] [Related]
34. Neurofibromin-deficient Schwann cells have increased lysophosphatidic acid dependent survival and migration-implications for increased neurofibroma formation during pregnancy.
Nebesio TD; Ming W; Chen S; Clegg T; Yuan J; Yang Y; Estwick SA; Li Y; Li X; Hingtgen CM; Yang FC
Glia; 2007 Apr; 55(5):527-36. PubMed ID: 17236191
[TBL] [Abstract][Full Text] [Related]
35. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
36. Trametinib Induces Neurofibroma Shrinkage and Enables Surgery.
Vaassen P; Dürr N; Röhrig A; Willing R; Rosenbaum T
Neuropediatrics; 2019 Oct; 50(5):300-303. PubMed ID: 31141829
[TBL] [Abstract][Full Text] [Related]
37. Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line.
Perrin GQ; Fishbein L; Thomson SA; Thomas SL; Stephens K; Garbern JY; DeVries GH; Yachnis AT; Wallace MR; Muir D
J Neurosci Res; 2007 May; 85(6):1347-57. PubMed ID: 17335073
[TBL] [Abstract][Full Text] [Related]
38. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.
Barrett SD; Bridges AJ; Dudley DT; Saltiel AR; Fergus JH; Flamme CM; Delaney AM; Kaufman M; LePage S; Leopold WR; Przybranowski SA; Sebolt-Leopold J; Van Becelaere K; Doherty AM; Kennedy RM; Marston D; Howard WA; Smith Y; Warmus JS; Tecle H
Bioorg Med Chem Lett; 2008 Dec; 18(24):6501-4. PubMed ID: 18952427
[TBL] [Abstract][Full Text] [Related]
39. Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.
Torti VR; Wojciechowicz D; Hu W; John-Baptiste A; Evering W; Troche G; Marroquin LD; Smeal T; Yamazaki S; Palmer CL; Burns-Naas LA; Bagrodia S
Mol Cancer Ther; 2012 Oct; 11(10):2274-83. PubMed ID: 22752429
[TBL] [Abstract][Full Text] [Related]
40. S100B and neurofibromin immunostaining and X-inactivation patterns of laser-microdissected cells indicate a multicellular origin of some NF1-associated neurofibromas.
Tucker T; Riccardi VM; Brown C; Fee J; Sutcliffe M; Vielkind J; Wechsler J; Wolkenstein P; Friedman JM
J Neurosci Res; 2011 Sep; 89(9):1451-60. PubMed ID: 21674567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
